(CAI) Caris Life Sciences, Common - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.268m USD | Total Return: -44.5% in 12m
Avg Turnover: 40.6M
Qual. Beats: 0
Rev. Trend: 97.6%
Warnings
Altman Z'' -6.17 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Caris Life Sciences, Inc. (CAI) is a Texas-based TechBio firm specializing in molecular profiling and artificial intelligence to advance precision oncology. The company utilizes Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS), and Whole Genome Sequencing (WGS) to develop diagnostic solutions for tissue and blood-based analysis. Its product suite includes platforms for early cancer detection, minimal residual disease monitoring, and therapy selection for hematological malignancies.
Operating within the Life Sciences Tools & Services sector, the company employs a business model that bridges diagnostic testing with biopharmaceutical research services. By integrating machine learning with high-throughput molecular data, the company provides actionable insights to hospitals and pharmaceutical partners. This sector is characterized by high capital intensity and a reliance on proprietary genomic databases to drive clinical decision-making.
Investors may find ValueRays quantitative tools useful for further analysis of this stocks performance metrics.
- Expansion of biopharma R&D partnerships drives high-margin data services revenue
- Medicare reimbursement rates for WES and WTS testing impact gross margins
- Adoption of multi-cancer early detection solutions accelerates market share growth
- High capital expenditures for AI infrastructure pressure short-term free cash flow
- Regulatory approval timelines for liquid biopsy platforms dictate commercialization speed
| Net Income: 34.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 244.7 > 1.0 |
| NWC/Revenue: 95.92% < 20% (prev 2.16%; Δ 93.76% < -1%) |
| CFO/TA 0.13 > 3% & CFO 147.4m > Net Income 34.0m |
| Net Debt (-165.8m) to EBITDA (104.5m): -1.59 < 3 |
| Current Ratio: 7.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (282.6m) vs 12m ago 10.90% < -2% |
| Gross Margin: 68.72% > 18% (prev 0.43%; Δ 6.83k% > 0.5%) |
| Asset Turnover: 124.8% > 50% (prev 138.0%; Δ -13.23% > 0%) |
| Interest Coverage Ratio: 1.47 > 6 (EBITDA TTM 104.5m / Interest Expense TTM 56.9m) |
| A: 0.75 (Total Current Assets 1.01b - Total Current Liabilities 143.9m) / Total Assets 1.16b |
| B: -2.19 (Retained Earnings -2.55b / Total Assets 1.16b) |
| C: 0.12 (EBIT TTM 83.8m / Avg Total Assets 727.0m) |
| D: -4.48 (Book Value of Equity -2.55b / Total Liabilities 568.9m) |
| Altman-Z'' = -6.17 = D |
| DSRI: 0.50 (Receivables 90.5m/80.2m, Revenue 907.3m/402.5m) |
| GMI: 0.63 (GM 68.72% / 43.44%) |
| AQI: 0.28 (AQ_t 0.06 / AQ_t-1 0.20) |
| SGI: 2.25 (Revenue 907.3m / 402.5m) |
| TATA: -0.10 (NI 34.0m - CFO 147.4m) / TA 1.16b) |
| Beneish M = -3.40 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 15.94 with a total of 2,368,494 shares traded.
Over the past week, the price has changed by +6.87%,
over one month by -24.15%,
over three months by -11.85% and
over the past year by -44.46%.
Caris Life Sciences, Common has no consensus analysts rating.
P/S = 4.7046
P/B = 7.1922
Revenue TTM = 907.3m USD
EBIT TTM = 83.8m USD
EBITDA TTM = 104.5m USD
Long Term Debt = 378.4m USD (from longTermDebt, last fiscal year)
Short Term Debt = 173k USD (from shortTermDebt, last quarter)
Debt = 427.9m USD (corrected: LT Debt 378.4m + ST Debt 173k) + Leases 49.2m
Net Debt = -165.8m USD (calculated: Debt 427.9m - CCE 593.7m)
Enterprise Value = 4.10b USD (4.27b + Debt 427.9m - CCE 593.7m)
Interest Coverage Ratio = 1.47 (Ebit TTM 83.8m / Interest Expense TTM 56.9m)
EV/FCF = 39.31x (Enterprise Value 4.10b / FCF TTM 104.4m)
FCF Yield = 2.54% (FCF TTM 104.4m / Enterprise Value 4.10b)
FCF Margin = 11.50% (FCF TTM 104.4m / Revenue TTM 907.3m)
Net Margin = 3.75% (Net Income TTM 34.0m / Revenue TTM 907.3m)
Gross Margin = 68.72% ((Revenue TTM 907.3m - Cost of Revenue TTM 283.8m) / Revenue TTM)
Gross Margin QoQ = 65.39% (prev 75.43%)
Tobins Q-Ratio = 3.53 (Enterprise Value 4.10b / Total Assets 1.16b)
Interest Expense / Debt = 13.29% (Interest Expense 56.9m / Debt 427.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = 66.2m (EBIT 83.8m * (1 - 21.00%))
Current Ratio = 4.75 (Total Current Assets 1.01b / Total Current Liabilities 213.7m)
Debt / Equity = 0.72 (Debt 427.9m / totalStockholderEquity, last quarter 593.5m)
Debt / EBITDA = -1.59 (Net Debt -165.8m / EBITDA 104.5m)
Debt / FCF = -1.59 (Net Debt -165.8m / FCF TTM 104.4m)
Total Stockholder Equity = 525.5m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.67% (Net Income 34.0m / Total Assets 1.16b)
RoE = 1.11% (Net Income TTM 34.0m / Total Stockholder Equity 3.07b)
RoCE = 2.43% (EBIT 83.8m / Capital Employed (Equity 3.07b + L.T.Debt 378.4m))
RoIC = 15.59% (NOPAT 66.2m / Invested Capital 425.0m)
WACC = 9.95% (E(4.27b)/V(4.70b) * Re(9.89%) + D(427.9m)/V(4.70b) * Rd(13.29%) * (1-Tc(0.21)))
Discount Rate = 9.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 82.81 | Cagr: 244.1%
[DCF] Terminal Value 70.05% ; FCFF base≈104.4m ; Y1≈104.8m ; Y5≈111.0m
[DCF] Fair Price = 5.39 (EV 1.36b - Net Debt -165.8m = Equity 1.52b / Shares 282.7m; r=9.95% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 97.56 | Revenue CAGR: 62.87% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.02 | Chg30d=N/A | Revisions=-20% | Analysts=9
EPS next Quarter (2026-09-30): EPS=0.05 | Chg30d=-20.14% | Revisions=N/A | Analysts=9
EPS current Year (2026-12-31): EPS=0.15 | Chg30d=+4.28% | Revisions=-20% | GrowthEPS=+135.9% | GrowthRev=+23.8%
EPS next Year (2027-12-31): EPS=0.37 | Chg30d=-0.24% | Revisions=-43% | GrowthEPS=+155.1% | GrowthRev=+20.3%
[Analyst] Revisions Ratio: -43%